Clinical Trials

NCT Number: NCT05156905 Phase: Phase 1 Trial Summary: The purpose of this study is to examine the safety and efficacy of cirmtuzumab in combination with standard of care docetaxel in patients with metastatic castration resistant prost – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of California, San Diego Acronym:

NCT Number: NCT05168618 Phase: Phase 2 Trial Summary: This phase II trial tests whether cabozantinib and atezolizumab work to shrink tumors in patients with castrate-resistant prostate cancer that had spread to other places in the bod – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Utah|National Cancer Institute (NCI) Acronym:

NCT Number: NCT05176483 Phase: Phase 1 Trial Summary: This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumor activity, and effect of bioma – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Exelixis Acronym: STELLAR-002

NCT Number: NCT05160597 Phase: Early Phase 1 Trial Summary: This early phase I trial studies how well an image-guided prostate biopsy using the imaging agent 68Ga-prostate-specific membrane antigen (PSMA)-11 with a positron emission tomogra – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Jonsson Comprehensive Cancer Center Acronym:

NCT Number: NCT05169970 Phase: Phase 2 Trial Summary: The researchers are doing this study to find out if stereotactic body radiation therapy (SBRT) without androgen deprivation therapy (ADT) is an effective treatment approach for peo – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Memorial Sloan Kettering Cancer Center Acronym:

NCT Number: NCT05162846 Phase: NA Trial Summary: The primary purpose of this study is to compare three interventions, two experimental and one standard of care (usual care), to see if the experimental interventions will increase – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Michigan Rogel Cancer Center Acronym: MiGHT

NCT Number: NCT05107674 Phase: Phase 1 Trial Summary: This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignanci – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Nurix Therapeutics, Inc. Acronym:

NCT Number: NCT05050084 Phase: Phase 3 Trial Summary: This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): NRG Oncology|National Cancer Institute (NCI) Acronym:

NCT Number: NCT05067777 Phase: Phase 2 Trial Summary: This phase II trial investigates the effect of massage in decreasing prostate cancer-related fatigue. Massage therapy has well known health benefits. This trial aims to find out if – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Utah|National Cancer Institute (NCI) Acronym: mPROSTATE

NCT Number: NCT05047536 Phase: Phase 1 Trial Summary: A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of KZ – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Kezar Life Sciences, Inc. Acronym: